GlassScriptPhysician profile
Sara Pinkerton
NPI 1558093393
$4,222.53
in general payments reported to CMS, 2019-2025
24 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $62.51 · 2024: $3,759 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183 · Travel and Lodging: $28.10 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.14 |
| Travel and Lodging | $28.10 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,101.43 | 2024 | Minimed 780g |
| Corcept Therapeutics | $466.66 | 2024 | Korlym |
| Lilly USA, LLC | $345.47 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Boston Scientific Corporation | $342.31 | 2025 | Wavewriter Alpha Prime 16, Intracept, Artisan |
| Novo Nordisk INC | $252.58 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $240.81 | 2024 | |
| Xeris Pharmaceuticals, INC. | $195.44 | 2024 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $190.20 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.28 | 2024 | Jardiance |
| Amgen INC. | $134.39 | 2024 | Repatha, Tepezza, Prolia |
| Insulet Corporation | $120.08 | 2024-2025 | Omnipod |
| Abbvie INC. | $100.22 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $92.00 | 2024 | Signifor Lar, Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $91.13 | 2024 | |
| Cequr Corporation | $76.30 | 2024-2025 | Cequr Simplicity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $52.92 | 2024 | |
| Antares Pharma, INC. | $52.79 | 2024 | Xyosted |
| Nevro Corp. | $48.40 | 2024 | Senza |
| Kyowa Kirin, INC. | $33.61 | 2024 | Crysvita |
| Dexcom, INC. | $30.51 | 2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $24.58 | 2024 | Ilet Bionic Pancreas |
| Tandem Diabetes Care, INC. | $21.33 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $21.19 | 2024 | Unithroid |
| Lexicon Pharmaceuticals, INC. | $15.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Pinkerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.